Broad antiviral and anti‐inflammatory efficacy of nafamostat against SARS‐CoV‐2 and seasonal coronaviruses in primary human bronchiolar epithelia

Broad antiviral and anti‐inflammatory efficacy of nafamostat against SARS‐CoV‐2 and seasonal coronaviruses in primary human bronchiolar epithelia

Abstract Antiviral strategies that target host systems needed for SARS‐CoV‐2 replication and pathogenesis may have therapeutic potential and help mitigate resistance development. Here, we evaluate nafamostat mesylate, a potent broad‐spectrum serine protease inhibitor that blocks host protease activa...

Full description

Bibliographic Details
Main Authors: Brian F. Niemeyer, Caitlin M. Miller, Carmen Ledesma‐Feliciano, James H. Morrison, Rocio Jimenez‐Valdes, Clarissa Clifton, Eric M. Poeschla, Kambez H. Benam
Format: Article
Language:English
Published: Wiley-VCH 2022-02-01
Series:Nano Select
Subjects:
SARS‐CoV‐2
Nafamostat
antiviral
anti‐inflammatory
airway epithelium
Online Access:https://doi.org/10.1002/nano.202100123

Internet

https://doi.org/10.1002/nano.202100123

Similar Items